Skip to main content

Month: March 2022

BoxScore Brands, Inc. Retains Global Leader RESPEC Company as its Geotech, Engineering and Resource Management Partner

LAS VEGAS, March 30, 2022 (GLOBE NEWSWIRE) — BoxScore Brands, Inc (OTC Pink Current: BOXS) (“BoxScore”, the “Company”) a U.S.-based renewable energy company focused on the extraction, refining, manufacturing, and distribution of precious technical minerals, announced today that they have retained RESPEC Company LLC as its Geotech, Engineering and Resource Management partner to assist in the exploration and development of its Lisbon Valley properties. “As announced on December 14, 2021, BoxScore obtained a technical report summarizing high lithium potential wells in our focus area. With that encouraging information, we began developing detailed plans to verify and demonstrate the presence of high potential brines. We spoke with several leading and experienced Geotech firms, ultimately providing our detailed scope and requirements...

Continue reading

ProPhase Labs Announces Record Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

Record Financial Results also expected for Q1 2022 Company to hold a conference call March 30, 2022, at 11:00AM ET Garden City, NY, March 30, 2022 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2021. Financial highlights for the full year ended December 31, 2021, include the following:Net revenue of $79.0 million for the year ended December 31, 2021, as compared to $14.5 million for the year ended December 31, 2020, an increase of approximately 445%.Net Income of $6.3 million, or $0.41 per share, for the year ended December 31, 2022, as compared to a net loss of $2.1 million, or $(0.18) per share, for the year ended December 31, 2020.Adjusted EBITDA income of...

Continue reading

Prof. Avi Schroeder Joins SciSparc’s Scientific Advisory Board to Support the Company’s Development of SCI-160 for Treating Pain

Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced the appointment of Professor Avi Schroeder as a member of the Company’s Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company’s top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor...

Continue reading

Quisitive Receives Mastercard Certification for Its LedgerPay Platform

TORONTO, March 30, 2022 (GLOBE NEWSWIRE) — Quisitive Technology Solutions, Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX:QUISF), a premier Microsoft solutions and payment solutions provider, today announced that it has officially received Mastercard certification to process credit and debit payments through its LedgerPay platform. Quisitive has successfully completed the certification process for its LedgerPay direct payment processing platform on the Mastercard network. After finalizing the configuration and installation of Mastercard’s hardware in mid-February and conducting joint certification tests, Quisitive is now fully approved to process transactions through Mastercard. Following the successful closing of the Company’s United States bank sponsorship with The Bancorp, and the recent Canadian bank sponsorship with...

Continue reading

IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announces it has selected the corporate communications expertise of IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities. Silo is committed to developing innovative solutions to address conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and...

Continue reading

SPYR Inc. (SPYR) Seizing Opportunity in Smart-Device Space

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SPYR Inc. (OTCQB: SPYR) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Smarter Homes, Smarter Cars, Smarter People,” please visit: https://nnw.fm/H6egy  The Internet of Things (IoT) has evolved over the last couple decades, weaving its way into daily life by providing increased utility and functionality for everyday items. Broadly speaking, IoT refers to the overarching technology that connects physical items (e.g., refrigerators, door locks, HVAC) to the internet so they can be controlled from a mobile or desktop app to provide real-time...

Continue reading

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World’s Largest Coronary Intervention Markets SANTA CLARA, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Shockwave C2 Coronary IVL Catheter received the regulatory approval in Japan. “Coronary IVL has clearly demonstrated the ability to safely and effectively treat severely calcified coronary lesions in a Japanese population,” said Shigeru Saito, MD, FACC, FSCAI, FJCC, Director of the Department of Cardiology and Catheterization Laboratory at the Shonan Kamakura General Hospital in Kamakura, Japan and principal investigator of Disrupt CAD IV, one of the studies...

Continue reading

CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) —  CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022. Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.Date:  Thursday, March 31, 2022Time:  5:30 am PT / 8:30...

Continue reading

Sugarmade Expands Cannabis Delivery Business and Launches Innovative Distribution Model with Dining Partnership

Fully Executed Agreements establish new hub for cannabis delivery in Hollywood Hills as well as partnership in popular restaurant trend as exclusive provider for on-site cannabis event space NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) (“Sugarmade”, “SGMD” or the “Company”) an emerging leader in the licensed cannabis sector, is pleased to announce the signing of Definitive Agreements (the “Agreements”) related to the Company’s expansion, including the establishment of majority ownership in a fully licensed new Hollywood cannabis delivery hub (the “Delivery Hub”) located on the world famous Sunset Strip as well as a minority stake in an expanding reservation-only restaurant brand with an adjacent private event space which will include cannabis...

Continue reading

CDSG PLANS 2022 LITHIUM EXPLORATION PROGRAM NEAR MASSIVE TLC PROJECT

Las Vegas, NV., March 30, 2022 (GLOBE NEWSWIRE) — China Dongsheng International Inc., (OTC Markets: CDSG) (the “Company” or “CDSG”) is currently reviewing and analyzing all geological data on its West End Lithium (“WEL”) project. The WEL project, next to the TLC Project being developed by American Lithium Corp. (LI.V), (OTCQB: LIACF), appears to be underlain by the same rock sequences. CDSG is planning a program of geological mapping, sampling, geochemical analysis, and drilling. The West End Lithium Project is located next to the same lithium mineralization hosted within the Miocene claystones of the Tonopah Lithium Claims (“TLC”) property held by American Lithium Corp. The TLC Project is a NI 43-101 compliant resource of 5.37 million tonnes of Lithium Carbonate Equivalent (“LCE”) in the Measured and Indicated category, which...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.